Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability.
A randomized trial was carried out to investigate the effect of 12 months administration of the gonadotrophin-releasing hormone agonist (GnRHa) Zoladex in combination with either placebo or medroxyprogesterone acetate (MPA) from the third month. Bone density, markers of bone resorption, symptoms and uterine volume were monitored in 24 women with symptomatic fibroids or menstrual problems. A total of 21 women were recruited to act as controls for the assessment of bone parameters. Vasomotor side-effects were reduced significantly in the MPA-treated group. The reduction in uterine volume in women with fibroids was not impaired by the addition of MPA. The bone markers osteocalcin and alkaline phosphatase were assessed in plasma, and the cross-links pyridinoline and deoxypyridinoline measured in urine. Changes in these markers are reported which suggest increases in bone resorption during the period of observation. Bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry at the spine and forearm. The net reduction in BMD at the spine in the treated groups was 4.30 +/- 0.59% at 6 months and 7.50 +/- 0.78% at 1 year, with no change in the control group. No change was seen in forearm BMD. No protective effect was observed when MPA was added. At 1 year after the completion of treatment, BMD remained significantly below baseline, and this has implications for the prolonged use of GnRHa.
Caird
L E
LE
Department of Obstetrics and Gynaecology, University of Edinburgh, Centre for Reproductive Biology, UK.
West
C P
CP
Lumsden
M A
MA
Hannan
W J
WJ
Gow
S M
SM
D000328:Adult; D000596:Amino Acids / Q000097:blood; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D005260:Female; D017273:Goserelin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007889:Leiomyoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D014599:Uterus / Q000187:drug effects / Q000473:pathology
D000596:Amino Acids; D015295:Antigens, Tumor-Associated, Carbohydrate; D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; C106882:CA602 antigen; D017273:Goserelin; C015484:pyridinoline; C036020:deoxypyridinoline; D017258:Medroxyprogesterone Acetate